Table 3.
Primary outcomes in one year after initial ablation (N=21,091)
| One year outcome | Gender | # Patients | # Events | Unadjusted Incidence Rate (per 100 person-years) | Unadjusted Hazard Ratio* (95%CI) | p | Adjusted Hazard Ratio*+ (95%CI) | p |
|---|---|---|---|---|---|---|---|---|
| All-cause hospitalization | Female | 6,137 | 1,955 | 46.1 | 1.23 | <0.00 | 1.14 | <.0001 |
|
|
||||||||
| Male | 14,954 | 4,017 | 36.9 | (1.65- | 1 | (1.07–1.20) | ||
|
| ||||||||
| Atrial fibrillation rehospitalization | Female | 6,137 | 825 | 16.8 | 1.14 | 0.001 | 1.12 | 0.009 |
|
|
||||||||
| Male | 14,954 | 1,792 | 14.7 | (1.05- | (1.03–1.22) | |||
|
| ||||||||
| Cardioversion | Female | 6,137 | 1,050 | 22.4 | 0.78 | <.000 | 0.75 | <.0001 |
|
|
||||||||
| Male | 14,954 | 3,203 | 28.9 | (0.73- | 1 | (0.70–0.81) | ||
|
| ||||||||
| Repeat ablation for atrial fibrillation | Female | 6,137 | 805 | 16.2 | 0.90 | 0.008 | 0.92 | 0.04 |
|
|
||||||||
| Male | 14,954 | 2,195 | 18.1 | (0.82- | (0.841- | |||
*
Reference group is male
+
Adjusted for age, Charlson Comorbidity Index score, CHF, hypertension, diabetes, stroke/TIA, prior MI, anemia, peripheral artery disease (PAD) or vascular disease, chronic kidney disease, year of ablation, insurance plan, and receipt of concomitant drug therapies (warfarin, dabigatran, clopidogrel, Class I and Class III anti-arrhythmic drugs, amiodarone, beta blockers, and calcium channel blockers)